News

Access and download our newsletters from the Newsletter Archive

 
 

As well as keeping you up to date with the latest developments within the life sciences sector, Bionow members can also post updates to the Bionow News page to promote themselves to over 300 Bionow member organisations and the UK Life Sciences sector.

Whether currently a member or not, keep up to date with all the latest news and events by registering to receive the Bionow newsletter.

Two groundbreaking drug discovery projects, supported by Medicines Discovery Catapult (MDC), have secured over £1m in funding from Innovate UK's Launchpad Northern Ireland programme.

Strategic partnership reinforces Inventya’s role in advancing biotechnology and regional innovation

Following the success of its first year, the Bionow Neuroscience conference was back at Bramall Lane in Sheffield.

On-Demand Webinar: Advancing Targeted MS Imaging with DESI XS and Xevo TQ Absolute

Suffolk-based cleanroom construction specialists the Guardtech Group have the perfect modular solution for clients who need to keep their host rooms intact

The FDA recently announced its plans to replace animal testing in the development of monoclonal antibodies with other methods, including human organoid models.

Northern Engineering Solutions employee, Hammed Shittu, has been officially accepted as a Member of the Chartered Institution of Building Services Engineers (MCIBSE).

July 8 2025 – Cambridge UK – Cresset, a leading provider of innovative solutions for the digitization of drug discovery, announces the acquisition of Molab.ai, a pioneer in artificial in...

Recent cyberattacks on UK retailers have shown just how damaging a breach can be — causing operational disruption, financial loss, and reputational harm. These threats are not limited to r...

The field of molecular glues has seen a rapid development in the past years and interest in molecular glue technology from the pharmaceutical industry appears to be on the rise, as indicated...

Our analysis of patent filings directed to treatments of neurodegenerative disorders (NDs) reveals a sharp increase in patent filings over the past decade.

Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S....

Our Valued Sponsors & Partners